: iStockAnalyst.com Symbols Feed

In Search of Healthcare Diamonds In The Rough

Mon, 12 Jan 2009 04:52:00 GMT

While we are not even halfway through January, the healthcare sector is already active with deal-making, ranging from the rumored $95 buyout of biotech giant Genetech (DNA) by Roche (RHHBY) to Endo's (ENDP) purchase of small-cap, specialty pharma Indevus (IDEV) to Sequenom's (SQNM) $41M offer for emerging diagnostic company EXACT Sciences (EXAS) – which was promptly rebuffed by EXACT's board after the market close on Monday on the promise of a better deal in the works for shareholders. Larger bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, and drug discovery technology platforms given the huge declines in the stock prices of small/micro-cap stocks in the healthcare sector. With that in mind, I sorted through the ETF Innovators indexes for a list of a dozen[More...]

Obagi Medical: Actionable Trading Call!

Mon, 28 Apr 2008 14:25:04 GMT

Obagi Medical (NASDAQ:OMPI) is getting mega-comments from two firm this morning ahead of their Q1 report scheduled for May 5.[More...]

Earnings, Oil Prices, & Bernanke

Tue, 16 Oct 2007 16:19:56 GMT

Good morning. Earnings, oil prices, and Bernanke are front and center and investors aren't very happy with what they're hearing. Premarket futures have been under pressure throughout the morning and are clearly pointing to a challenging day ahead for the bulls. Earnings reports out this morning offer a mixed outlook with a number of earnings surprises on the downside (ERIC, WFC, KEY, STLY, JEF, DNA) as well as upside (JNJ, USB, STT, FRX, PII). Crude oil prices are up again and have been up +9% over the past week. Also

This novel BPO technology has drawn the interest and product adoption of key opinion leaders and top acne prescribing dermatologists as evidenced by the success of the Obagi CLENZIderm® M.D. brand in the physician-dispense channel," said Steve Carlson, President and CEO.

[More...]